DOVA تصريحات هيئة الأوراق المالية والبورصات - Dova Pharmaceuticals, Inc.- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

LEI	5299002ZW0UYRIRJ3226
CIK	1685071

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Dova Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

November 22, 2019	15-12B	DOVA / Dova Pharmaceuticals, Inc. 15-12B - - FORM 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38135 DOVA PHARMACEUTICALS, INC. (Exact name of registrant as specified
November 15, 2019	SC 13G/A	DOVA / Dova Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 4 TO SCHEDULE 13G Passive Investment Amendment No. 4 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Dova Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 25985T 10 2 (CUSIP Number) November 12, 2019 (Date of Event Which Requires Filing of this Statement) Check
November 12, 2019	POS AM	DOVA / Dova Pharmaceuticals, Inc. POS AM - - AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on November 12, 2019 Registration No.
November 12, 2019	S-8 POS	DOVA / Dova Pharmaceuticals, Inc. S-8 POS - - AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on November 12, 2019 Registration No.
November 12, 2019	S-8 POS	DOVA / Dova Pharmaceuticals, Inc. S-8 POS - - AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on November 12, 2019 Registration No.
November 12, 2019	SC 14D9/A	DOVA / Dova Pharmaceuticals, Inc. SC 14D9/A - - AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D‑9 (Rule 14d‑101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) DOVA PHARMACEUTICALS, INC. (Name of Subject Company) DOVA PHARMACEUTICALS, INC. (Name of Person(s) Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Sec
November 12, 2019	EX-3.1	Amended and Restated Certificate of Incorporation of Dova Pharmaceuticals, Inc., dated as of November 12, 2019. EX-3.1 2 ex3-1.htm AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DOVA PHARMACEUTICALS, INC. FIRST: The name of the corporation (hereinafter called the “Corporation”) is Dova Pharmaceuticals, Inc. SECOND: The address, including street, number, city, and county, of the registered office of the Corporation in the State of Delaware i
November 12, 2019	EX-3.2	Amended and Restated Bylaws of Dova Pharmaceuticals, Inc., dated as of November 12, 2019. Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF DOVA PHARMACEUTICALS, INC. ARTICLE I Meetings of Stockholders; Stockholders’ Consent in Lieu of Meeting SECTION 1.01. Annual Meeting. The annual meeting of the stockholders for the election of directors, and for the transaction of such other business as may properly come before the meeting, shall be held at such place, date and hour as shall be fixed by
November 12, 2019	8-K	Regulation FD Disclosure, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2019 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38135 81-3858961 (State or Other Jurisdiction of Incorporation) (Commis
November 12, 2019	EX-99.(A)(5)(D)	Stockholm, Sweden, 9 November 2019 Exhibit (a)(5)(D) PRESS RELEASE Stockholm, Sweden, 9 November 2019 Sobi successfully completes tender offer for all outstanding shares of Dova Pharmaceuticals Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that its indirect wholly owned subsidiary Dragonfly Acquisition Corp.
November 12, 2019	SC TO-T/A	SWTUY / Swedish Orphan Biovitrum AB SC TO-T/A - - AMENDMENT NO. 2 SC TO-T/A 1 sctota.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) DOVA PHARMACEUTICALS, INC. (Name of Subject Company) DRAGONFLY ACQUISITION CORP. (Offeror) A Wholly Owned Subsidiary of DRAGONFLY HOLDING CORP. (Parent of O
November 12, 2019	EX-99.(A)(5)(E)	Joint Press Release, dated November 12, 2019 (incorporated by reference to Exhibit (a)(5)(E) of the Schedule TO/A filed with the SEC by Sobi, Dragonfly Holding Corp. and Dragonfly Acquisition Corp. on November 12, 2019). EX-99.(A)(5)(E) 3 ex99a5e.htm PRESS RELEASE Exhibit (a)(5)(E) PRESS RELEASE Stockholm, Sweden, 12 November 2019 Sobi successfully completes acquisition of Dova Pharmaceuticals Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Dova Pharmaceuticals, Inc. (Dova) (NASDAQ: DOVA) announced today the completion of the acquisition of Dova by Sobi. Following the completion of Sobi’s successful tend
November 12, 2019	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38135 DOVA PHARMACEUTICALS,
November 1, 2019	SC TO-T/A	SWTUY / Swedish Orphan Biovitrum AB SC TO-T/A - - AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) DOVA PHARMACEUTICALS, INC. (Name of Subject Company) DRAGONFLY ACQUISITION CORP. (Offeror) A Wholly Owned Subsidiary of DRAGONFLY HOLDING CORP. (Parent of Offeror) And An Indirect Wholly Owned Su
November 1, 2019	SC 14D9/A	DOVA / Dova Pharmaceuticals, Inc. SC 14D9/A - - SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) DOVA PHARMACEUTICALS, INC. (Name of Subject Company) DOVA PHARMACEUTICALS, INC. (Name of Person(s) Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Sec
October 11, 2019	SC 14D9	DOVA / Dova Pharmaceuticals, Inc. SC 14D9 - - SC 14D9 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
October 11, 2019	EX-99.(A)(1)(E)	Offer to Purchase for Cash All Outstanding Shares of Common Stock of DOVA PHARMACEUTICALS, INC. at $27.50 per share, net in cash, plus one non-transferable contingent value right for each share, which represents the contractual right to receive a cas Exhibit (a)(1)(E) Offer to Purchase for Cash All Outstanding Shares of Common Stock of DOVA PHARMACEUTICALS, INC.
October 11, 2019	EX-99.(A)(1)(B)	Letter of Transmittal to Tender Shares of Common Stock of DOVA PHARMACEUTICALS, INC. at $27.50 per share, net in cash, plus one non-transferable contingent value right for each share, which represents the contractual right to receive a cash payment o QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of DOVA PHARMACEUTICALS, INC.
October 11, 2019	EX-99.(A)(1)(C)	Notice of Guaranteed Delivery for Offer to Purchase for Cash All Outstanding Shares of Common Stock of DOVA PHARMACEUTICALS, INC. at $27.50 per share, net in cash, plus one non-transferable contingent value right for each share, which represents the EX-99.(A)(1)(C) 4 a2239851zex-99a1c.htm EX-99.(A)(1)(C) Exhibit (a)(1)(c) Notice of Guaranteed Delivery for Offer to Purchase for Cash All Outstanding Shares of Common Stock of DOVA PHARMACEUTICALS, INC. at $27.50 per share, net in cash, plus one non-transferable contingent value right for each share, which represents the contractual right to receive a cash payment of $1.50 per share upon the achi
October 11, 2019	EX-99.(D)(4)	TENDER AND SUPPORT AGREEMENT EX-99.(D)(4) 10 a2239851zex-99d4.htm EX-99.(D)(4) Exhibit (d)(4) EXECUTION VERSION TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of September 30, 2019, is by and among Swedish Orphan Biovitrum AB (publ), a Swedish public limited liability company (“Parent”), Dragonfly Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of
October 11, 2019	EX-99.(D)(5)	August 19, 2019 Exhibit (d)(5) STRICTLY CONFIDENTIAL August 19, 2019 CONFIDENTIAL Swedish Orphan Biovitrum AB (publ) Tomtebodavägen 23A SE-112 76 Stockholm Sweden Attn: Mr.
October 11, 2019	EX-99.(A)(1)(D)	Offer to Purchase for Cash All Outstanding Shares of Common Stock of DOVA PHARMACEUTICALS, INC. at $27.50 per share, net in cash, plus one non-transferable contingent value right for each share, which represents the contractual right to receive a cas EX-99.(A)(1)(D) 5 a2239851zex-99a1d.htm EX-99.(A)(1)(D) Exhibit (a)(1)(D) Offer to Purchase for Cash All Outstanding Shares of Common Stock of DOVA PHARMACEUTICALS, INC. at $27.50 per share, net in cash, plus one non-transferable contingent value right for each share, which represents the contractual right to receive a cash payment of $1.50 per share upon the achievement of a specified milestone,
October 11, 2019	EX-99.(A)(1)(A)	Offer to Purchase for Cash All Outstanding Shares of Common Stock of Dova Pharmaceuticals, Inc. at $27.50 per share, net in cash, plus one non-transferable contingent value right for each share, which represents the contractual right to receive a cas QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Dova Pharmaceuticals, Inc.
October 11, 2019	EX-99.(A)(1)(F)	This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely by Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below).
October 11, 2019	EX-99.(A)(5)(C)	1 Exhibit (a)(5)(C) PRESS RELEASE Stockholm, Sweden, 11 October 2019 Sobi commences tender offer for all outstanding shares of Dova Pharmaceuticals Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that it has commenced a tender offer through its indirect wholly owned subsidiary Dragonfly Acquisition Corp.
October 11, 2019	EX-99.(D)(3)	TENDER AND SUPPORT AGREEMENT EX-99.(D)(3) 9 a2239851zex-99d3.htm EX-99.(D)(3) Exhibit (d)(3) EXECUTION VERSION TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of September 30, 2019, is by and among Swedish Orphan Biovitrum AB (publ), a Swedish public limited liability company (“Parent”), Dragonfly Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of P
October 11, 2019	SC TO-T	SWTUY / Swedish Orphan Biovitrum AB SC TO-T - - SC TO-T SC TO-T 1 a2239851zscto-t.htm SC TO-T QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DOVA PHARMACEUTICALS, INC. (Name of Subject Company) DRAGONFLY ACQUISITION CORP. (Offeror) A Wholly Owned Sub
October 3, 2019	SC14D9C	DOVA / Dova Pharmaceuticals, Inc. SC14D9C - - SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Dova Pharmaceuticals, Inc. (Name of Subject Company) Dova Pharmaceuticals, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 25985T 10
October 3, 2019	EX-2.1	Agreement and Plan of Merger, dated as of September 30, 2019, by and among Dova Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB (publ) and Dragonfly Acquisition Corp (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed with the SEC on October 3, 2019). Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among: DOVA PHARMACEUTICALS, INC., SWEDISH ORPHAN BIOVITRUM AB (PUBL) and DRAGONFLY ACQUISITION CORP. September 30, 2019 TABLE OF CONTENTS Page SECTION 1. CERTAIN DEFINITIONS 2 SECTION 2. THE OFFER 14 2.1 The Offer 14 2.2 Company Actions 17 SECTION 3. MERGER TRANSACTION 18 3.1 Merger of Purchaser into the Company 18 3.2 Effect of th
October 3, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2019 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File
October 1, 2019	SC TO-C	SWTUY / Swedish Orphan Biovitrum AB SC TO-C - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DOVA PHARMACEUTICALS, INC. (Name of Subject Company) DRAGONFLY ACQUISITION CORP. (Offeror) A Wholly Owned Subsidiary of DRAGONFLY HOLDING CORP. (Parent of Offeror) And An Indirect Wholly Owned Subsidiary of SWEDIS
October 1, 2019	EX-99.1	30th September 2019 Introduction to Sobi Sobi in brief 2 Biopharmaceutical company with a focus on rare diseasesBusiness areas:HaematologyImmunologyPresent in more than 25 countries, delivering treatments to patients in over 70 countries around the w Exhibit 99.1 The following presentation was made available to employees of Dova Pharmaceuticals, Inc.: Notice to Investors The tender offer for the outstanding shares of Dova Pharmaceuticals Inc. (“Dova”) common stock has not yet commenced. This presentation is being given to Dova’s employees for informational purposes only and such presentation is neither an offer to purchase nor a solicitation o
October 1, 2019	SC TO-C	DOVA / Dova Pharmaceuticals, Inc. SC TO-C - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DOVA PHARMACEUTICALS, INC. (Name of Subject Company) DRAGONFLY ACQUISITION CORP. (Offeror) A Wholly Owned Subsidiary of DRAGONFLY HOLDING CORP. (Parent of Offeror) And An Indirect Wholly Owned Subsidiary of SWEDIS
October 1, 2019	EX-99.1	Stockholm, Sweden, 30 September 2019 EX-99.1 2 ex99-1.htm PRESS RELEASE Exhibit 99.1 PRESS RELEASE Stockholm, Sweden, 30 September 2019 Sobi to acquire Dova Pharmaceuticals creating a global growth platform in haematology Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) by means of a tender offer. The consideration consists of an upfront p
September 30, 2019	SC14D9C	DOVA / Dova Pharmaceuticals, Inc. SC14D9C - - SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Dova Pharmaceuticals, Inc. (Name of Subject Company) Dova Pharmaceuticals, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 25985T 10
September 30, 2019	EX-99.1	Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi) Exhibit 99.1 Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi) · Consideration of up to $29.00 per share includes $27.50 per share in upfront cash and an additional $1.50 per share upon regulatory approval of DOPTELET® for chemotherapy-induced thrombocytopenia (CIT) as a Contingent Value Right (CVR) for a total potential consideration of up to $915 million on a fully dilute
September 30, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2019 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File
August 6, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2019 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File Num
August 6, 2019	EX-99.1	Dova Pharmaceuticals Reports Second Quarter 2019 Operating and Financial Results Dova Pharmaceuticals Reports Second Quarter 2019 Operating and Financial Results • DOPTELET® (avatrombopag) approved by U.
August 6, 2019	EX-10.3	Lease amendment, dated as of May 13, 2019, between Dova Pharmaceuticals, Inc. and Pine Forest 240 TT, LLC FIRST AMENDMENT TO OFFICE LEASE AGREEMENT THIS FIRST AMENDMENT TO OFFICE LEASE AGREEMENT (this “First Amendment”) is made this 13th day of May, 2019 (the “Effective Date”), by and between PINE FOREST 240 TT, LLC, a Delaware limited liability company (“Landlord”), and DOVA PHARMACEUTICALS, INC.
August 6, 2019	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38135 DOVA PHARMACEUTICALS, INC.
June 27, 2019	EX-99.1	Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET® (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP) Company Strengthens Thrombocytopenia Portfolio with ITP Approval and Expanded Partner Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET® (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP) Company Strengthens Thrombocytopenia Portfolio with ITP Approval and Expanded Partnership with Salix for Chronic Liver Disease (CLD) Indication Company to Host Conference Call at 9am EST DURHAM, N.
June 27, 2019	EX-10.1	First Amendment to the Co-Promotion Agreement, dated June 27, 2019. FIRST AMENDMENT TO THE CO-PROMOTION AGREEMENT by and between DOVA PHARMACEUTICALS, INC.
June 27, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2019 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File Numb
May 7, 2019	EX-10.2	Amended and Restated Loan and Security Agreement, dated as of May 6, 2019, by and among Dova Pharmaceuticals, Inc., AkaRx, In., Silicon Valley Bank and WestRiver Innovation Lending Fund VIII, L.P Exhibit 10.2 AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of May 6, 2019 (the “Effective Date”), among (a) SILICON VALLEY BANK, a California corporation, in its capacity as administrative agent and collateral agent (“Agent”), (b) SILICON VALLEY BANK, a California corporation, as a lender (“SVB”), (c) WESTRIVER IN
May 7, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 dovaq120198-kearningsrelea.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2019 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorpo
May 7, 2019	EX-99.1	Dova Pharmaceuticals Reports First Quarter 2019 Operating and Financial Results EX-99.1 2 dovaq12019earningsrelease.htm EXHIBIT 99.1 Dova Pharmaceuticals Reports First Quarter 2019 Operating and Financial Results • First Quarter 2019 net product sales of $4.0 million from DOPTELET® (avatrombopag) • New marketing campaign launched early in second quarter for the treatment of thrombocytopenia associated with chronic liver disease (CLD) • sNDA under review by the U.S. FDA for DO
May 7, 2019	10-Q	DOVA / Dova Pharmaceuticals, Inc. 10-Q Quarterly Report 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38135 DOVA PHARMACEUTICALS, INC.
April 26, 2019	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2019 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File Num
March 15, 2019	DEFA14A	DOVA / Dova Pharmaceuticals, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 15, 2019	DEF 14A	DOVA / Dova Pharmaceuticals, Inc. DEF 14A QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 5, 2019	EX-99.1	Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Operating and Financial Results DOPTELET® (avatrombopag) approved May 21, 2018 and launched June 4, 2018 Net product sales from DOPTELET were $2.8 million in the fourth quarter of 2018 an EX-99.1 2 dovaq42018earningsrelease.htm EXHIBIT 99.1 Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Operating and Financial Results DOPTELET® (avatrombopag) approved May 21, 2018 and launched June 4, 2018 Net product sales from DOPTELET were $2.8 million in the fourth quarter of 2018 and $7.7 million for the full year ended December 31, 2018 sNDA accepted for review by FDA for DOPT
March 5, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File N
March 5, 2019	10-K	DOVA / Dova Pharmaceuticals, Inc. 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001- 38135 DOVA
March 5, 2019	EX-10.29	Employment Agreement, by and between the Company and Jason Hoitt, dated as of December 17, 2018 Exhibit 10.29 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective December 17, 2018 (the “Effective Date”), which shall be Employee’s commencement of employment, by and between Dova Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Jason Hoitt (the “Employee”). The Company desires to employ Employee in the capacity of full-time Chief Commercia
March 5, 2019	EX-10.28	Employment Agreement, by and between the Company and David S. Zaccardelli, dated as of December 17, 2018 Exhibit 10.28 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective December 17, 2018 (the “Effective Date”), which shall be Employee’s commencement of employment, by and between Dova Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and David S. Zaccardelli (the “Employee”). The Company desires to employ Employee in the capacity of full-time Presid
February 14, 2019	SC 13G/A	DOVA / Dova Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 3 TO SCHEDULE 13G Passive Investment SC 13G/A 1 d673972dsc13ga.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Dova Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 25985T 10 2 (CUSIP Number) December 31, 2018 (Date of Event Which Requires F
February 8, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2019 Dova Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38135 81-3858961 (State or other jurisdiction of incorporation or organ
February 8, 2019	EX-99.1	DOVA PHARMACEUTICALS, INC. OFFICER CHANGE IN CONTROL SEVERANCE BENEFIT PLAN Exhibit 99.1 DOVA PHARMACEUTICALS, INC. OFFICER CHANGE IN CONTROL SEVERANCE BENEFIT PLAN Section 1. INTRODUCTION. This Dova Pharmaceuticals, Inc. Officer Change in Control Severance Benefit Plan (the “Plan”) is hereby adopted effective as of February 5, 2019 (the “Effective Date”). The purpose of the Plan is to provide for the payment of severance benefits to certain eligible executive officers of
February 6, 2019	SC 13G/A	DOVA / Dova Pharmaceuticals, Inc. / Manning Paul B - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 1)* Dova Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 25985T 10 2 (CUSIP Number) December 31, 2
January 7, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2019 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File Nu
January 7, 2019	EX-99.1	J.P. Morgan 37th Annual Healthcare Conference January 8, 2019 David Zaccardelli, PharmD Chief Executive Officer Exhibit 99.1 J.P. Morgan 37th Annual Healthcare Conference January 8, 2019 David Zaccardelli, PharmD Chief Executive Officer Disclaimer Certain information contained in this presentation relates to or is based on studies, surveys and other data obtained from third-party sources and Dova’s own internal estimates and research. While Dova believes these sources to be reliable as of the date of this p
December 20, 2018	EX-10.2	Form of Restricted Stock Unit Grant Notice (previously filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-38135), filed with the Commission on December 20, 2018, and incorporated by reference herein) Exhibit 10.2 DOVA PHARMACEUTICALS RESTRICTED STOCK UNIT GRANT NOTICE (AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN) Dova Pharmaceuticals (the “Company”), pursuant to its Amended and Restated 2017 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Aw
December 20, 2018	EX-99.1	Dova Pharmaceuticals Announces Management Changes Dr. David Zaccardelli appointed President and Chief Executive Officer Jason Hoitt appointed Chief Commercial Officer Company provides preliminary estimates of fourth quarter net product sales of $2.4 Exhibit 99.1 Dova Pharmaceuticals Announces Management Changes Dr. David Zaccardelli appointed President and Chief Executive Officer Jason Hoitt appointed Chief Commercial Officer Company provides preliminary estimates of fourth quarter net product sales of $2.4 to $2.7 million for DOPTELET® (avatrombopag) DURHAM, NC, December 17, 2018 — Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical
December 20, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38135 81-3858961 (State or Other Jurisdiction (Commission (IRS Employe
December 20, 2018	EX-10.1	Amended and Restated 2017 Equity Incentive Plan, as amended (previously filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-38135), filed with the Commission on December 20, 2018 and incorporated by reference herein) Exhibit 10.1 DOVA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 14, 2017 APPROVED BY THE STOCKHOLDERS: JUNE 15, 2017 AMENDED BY THE COMPENSATION COMMITTEE: DECEMBER 19, 2018 IPO DATE: JUNE 28, 2017 1. GENERAL. Amendment and Restatement of Prior Plan. The Plan is intended as the amendment and restatement of the Dova Pharmaceuticals, In
December 20, 2018	EX-10.3	Second Amended and Restated Non-Employee Director Compensation Policy (previously filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K (File No. 001-38135), filed with the Commission on December 20, 2018, and incorporated by reference herein) Exhibit 10.3 DOVA PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY EFFECTIVE DECEMBER 19, 2019 Each member of the Board of Directors (the “Board”) of Dova Pharmaceuticals, Inc. (the “Company”) that the Board has determined is an Independent Director as defined by Nasdaq Listing Rule 5605(a)(2) (each such member, an “Eligible Director”) will receive the co
November 8, 2018	EX-99.1	Dova Pharmaceuticals Reports Third Quarter 2018 Operating and Financial Results Third quarter net product sales of $2.9 million from DOPTELET® (avatrombopag); 335 cumulative unique prescribers from launch through September 30, 2018 sNDA accepted for EX-99.1 2 dovaq32018earningsrelease.htm EXHIBIT 99.1 Dova Pharmaceuticals Reports Third Quarter 2018 Operating and Financial Results Third quarter net product sales of $2.9 million from DOPTELET® (avatrombopag); 335 cumulative unique prescribers from launch through September 30, 2018 sNDA accepted for review by FDA for DOPTELET for the treatment of chronic immune thrombocytopenia (ITP) Entered int
November 8, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 dovaq32018form8-kearningsr.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of In
November 8, 2018	EX-10.3	Amended and Restated Transition Services Agreement by and between Eisai, Inc. and AkaRx, Inc., dated April 1, 2018 (previously filed as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q (File No. 001-38135), filed with the Commission on November 8, 2018 and incorporated by reference herein) Exhibit 10.3 AMENDED AND RESTATED TRANSITION SERVICES AGREEMENT by and between Eisai Inc. and AkaRx, Inc. Dated as of April 1, 2018 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES
November 8, 2018	10-Q	DOVA / Dova Pharmaceuticals, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38135 DOVA PHARMACEUTICALS,
November 8, 2018	EX-10.2	Co-Promotion Agreement, dated as of September 26, 2018, by and between the Company and Valeant Pharmaceuticals North America LLC (previously filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-38135), filed with the Commission on November 8, 2018 and incorporated by reference herein) Exhibit 10.2 CO-PROMOTION AGREEMENT by and between DOVA PHARMACEUTICALS, INC. and VALEANT PHARMACEUTICALS NORTH AMERICA LLC September 26, 2018 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
October 4, 2018	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File Nu
October 2, 2018	EX-99.1	Corporate Presentation October 2018 Exhibit 99.1 Corporate Presentation October 2018 Disclaimer Certain information contained in this presentation relates to or is based on studies, surveys and other data obtained from third-party sources and Dova’s own internal estimates and research. While Dova believes these sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation
October 2, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File Nu
September 27, 2018	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38135 81-3858961 (State or Other Jurisdiction of Incorporation) (Comm
August 9, 2018	424B5	Common Stock Preferred Stock Debt Securities Warrants 424B5 1 a2236426z424b5.htm 424B5 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-226403 PROSPECTUS $300,000,000 Common Stock Preferred Stock Debt Securities Warrants From time to time, we may offer up to $300,000,000 of any combination of the securities described in this prospectus in one or more off
August 9, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38135 81-3858961 (State or Other Jurisdiction of Incorporation) (Commissi
August 9, 2018	EX-99.1	Dova Pharmaceuticals Reports Second Quarter 2018 Operating and Financial Results DOPTELET approved by FDA on May 21, 2018 DOPTELET launched on June 4, 2018 Conference call scheduled for 4:30 p.m. ET today Investor & Analyst Day scheduled for Septembe EX-99.1 2 a18-177846ex99d1.htm EX-99.1 Exhibit 99.1 Dova Pharmaceuticals Reports Second Quarter 2018 Operating and Financial Results DOPTELET approved by FDA on May 21, 2018 DOPTELET launched on June 4, 2018 Conference call scheduled for 4:30 p.m. ET today Investor & Analyst Day scheduled for September 20, 2018 in NYC DURHAM, NC, August 9, 2018 — Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharma
August 9, 2018	424B5	Common Stock 424B5 1 a2236429z424b5.htm 424B5 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-226403 PROSPECTUS $100,000,000 Common Stock We have entered into a sales agreement with Stifel, Nicolaus & Company, Incorporated, or Stifel, relating to shares of our common stock offered by this prospectus. In accordanc
August 9, 2018	10-Q	DOVA / Dova Pharmaceuticals, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38135 DOVA PHARMACEUTICALS, INC.
August 9, 2018	EX-10.3	Commercial Outsourcing Master Services Agreement, dated as of March 1, 2018, by and between the Company and Integrated Commercialization Solutions, LLC, as amended (previously filed as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q (File No. 001-38135), filed with the Commission on August 9, 2018, and incorporated by reference herein) Exhibit 10.3 FIRST AMENDMENT TO COMMERCIAL OUTSOURCING MASTER SERVICES AGREEMENT INTERIM DIRECT MODEL This First Amendment to the Commercial Outsourcing Master Services Agreement (this “Amendment”) is between Dova Pharmaceuticals, Inc. (the “Company”) and Integrated Commercialization Solutions, LLC (“ICS”). This Amendment is effective as of March 1, 2018 (the “Amendment Effective Date”). RECITALS
August 9, 2018	EX-10.1	Loan and Security Agreement, dated as of April 17, 2018, by and between the Company, AkaRx, Inc. and Silicon Valley Bank (previously filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-38135), filed with the Commission on August 9, 2018, and incorporated by reference herein) Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated and is effective as of April 17, 2018 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and DOVA PHARMACEUTICALS, INC., a Delaware corporation (“Dova”) and AKARX, INC., a Delaware corporation (“Akarx” and together with Dova, each a “Co-Borrower” and collectivel
August 6, 2018	CORRESP	DOVA / Dova Pharmaceuticals, Inc. CORRESP 240 Leigh Farm Road, Suite 245 Durham, NC 27707 August 6, 2018 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeff Gabor Re: Dova Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed July 27, 2018 File No. 333-226403 Acceleration Request Requested Date: August 8, 2018 Requested Time: 4:00 P.M. Eastern Time
July 27, 2018	EX-4.2	Form of Indenture, between the Registrant and one or more trustees to be named. EXHIBIT 4.2 DOVA PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8
July 27, 2018	S-3	DOVA / Dova Pharmaceuticals, Inc. S-3 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on July 27, 2018 Registration No.
July 27, 2018	EX-4.4	Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.4 DOVA PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF DOVA PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between DOVA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and ex
July 27, 2018	EX-4.5	Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.5 4 a2236323zex-45.htm EX-4.5 Exhibit 4.5 DOVA PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF DOVA PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between DOVA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [na
July 27, 2018	EX-4.6	Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.6 DOVA PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF DOVA PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [·], between DOVA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organiz
July 27, 2018	S-8	DOVA / Dova Pharmaceuticals, Inc. S-8 As filed with the Securities and Exchange Commission on July 27, 2018 Registration No.
July 27, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File Numb
July 27, 2018	EX-10.1	At-the-Market Equity Offering Sales Agreement dated as of July 27, 2018, between the Registrant and Stifel, Nicolaus & Company, Incorporated (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-38135), filed with the SEC on July 27, 2018). Exhibit 10.1 Dova Pharmaceuticals, Inc. Common Stock ($0.001 par value per share) AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT July 27, 2018 STIFEL, NICOLAUS & COMPANY, INCORPORATED 787 7th Avenue, 11th Floor New York, NY 10019 Ladies and Gentlemen: Dova Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell fr
June 25, 2018	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File Numb
June 25, 2018	EX-99.1	Nancy J. Wysenski Joins Dova Pharmaceuticals’ Board of Directors Exhibit 99.1 Nancy J. Wysenski Joins Dova Pharmaceuticals’ Board of Directors DURHAM, NC, June 25, 2018 — Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Nancy J. Wysenski will join Dova’s Board of Directors effective immediately. In addition to her board responsibilities, Ms. Wysenki will also serve on both the Compensation Committee and the Nominating and Corporate Governance Comm
June 20, 2018	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File Numb
June 7, 2018	SC 13G/A	DOVA / Dova Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment Amendment No. 2 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Dova Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 25985T 10 2 (CUSIP Number) June 4, 2018 (Date of Event Which Requires Filing of this Statement) Check the
May 24, 2018	EX-10.1	Office Lease Agreement, dated as of May 22, 2018, by and between the Registrant and Pine Forest 240 TT, LLC (previously filed as Exhibit 10.1 to the Registrants Current Report on Form 8-K (File No. 001-38135), filed with the Commission on May 24, 2018, and incorporated by reference herein) EX-10.1 2 a18-142831ex10d1.htm EX-10.1 Exhibit 10.1 OFFICE LEASE AGREEMENT BY AND BETWEEN PINE FOREST 240 TT, LLC (AS LANDLORD) AND DOVA PHARMACEUTICALS, INC. (AS TENANT) 240 Leigh Farm Road Durham, North Carolina 27517 HOLLAND + KNIGHT LLP 800 17th Street, N.W. Suite 1100 Washington, DC 20006 Phone: (202) 955-3000 Fax: (202) 955-5564 TABLE OF CONTENTS Page 1. BASIC LEASE TERMS 1 2. DESCRIPTION OF
May 24, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File Numbe
May 21, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38135 81-3858961 (State or Other Jurisdiction of Incorporation) (Commission
May 21, 2018	EX-99.2	DOPTELET FDA Approval Conference Call May 21, 2018 1:30 p.m. (PST) / 4:30 p.m. (EST) EX-99.2 3 a18-130541ex99d2.htm EX-99.2 Exhibit 99.2 DOPTELET FDA Approval Conference Call May 21, 2018 1:30 p.m. (PST) / 4:30 p.m. (EST) Disclaimer Certain information contained in this presentation relates to or is based on studies, surveys and other data obtained from third-party sources and Dova’s own internal estimates and research. While Dova believes these sources to be reliable as of the da
May 21, 2018	EX-99.1	Dova Pharmaceuticals Announces U.S. FDA Approval of DOPTELET® (avatrombopag) Company to Host Conference Call at 4:30 pm Exhibit 99.1 Dova Pharmaceuticals Announces U.S. FDA Approval of DOPTELET® (avatrombopag) Company to Host Conference Call at 4:30 pm DURHAM, NC, May 21, 2018 — Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced the U.S. Food and Drug Administration (FDA) has completed their Priority Review and approved DOPTELET® (avatrombopag) for the treatment of thrombocytopenia in adult patients with chr
May 9, 2018	EX-99.1	Dova Pharmaceuticals Reports First Quarter 2018 Operating and Financial Results PDUFA date for avatrombopag of May 21, 2018 Conference call scheduled for 4:30 p.m. ET today Exhibit 99.1 Dova Pharmaceuticals Reports First Quarter 2018 Operating and Financial Results PDUFA date for avatrombopag of May 21, 2018 Conference call scheduled for 4:30 p.m. ET today DURHAM, NC, May 9, 2018 — Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need
May 9, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File Number
May 9, 2018	EX-10.3	Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.3 DOVA PHARMACEUTICALS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY EFFECTIVE JANUARY 1, 2018 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Dova Pharmaceuticals, Inc. (the “Company”) or any of its subsidiaries and is not affiliated with an entity that beneficially owns 5% or more of the Company’s outstanding shares
May 9, 2018	10-Q	DOVA / Dova Pharmaceuticals, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38135 DOVA PHARMACEUTICALS, INC.
May 9, 2018	EX-10.2	Amendment to Services Agreement by and between the Company and PBM Capital Group, LLC, dated as of March 29, 2018 (previously filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-38135), filed with the Commission on May 9, 2018, and incorporated by reference herein) Exhibit 10.2 AMENDMENT TO SERVICES AGREEMENT This Amendment to Services Agreement (this “Amendment”), dated as of March 29, 2018, is made by and between Dova Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and PBM Capital Group, LLC, a Delaware limited liability company (“PBM”). Capitalized terms used but not otherwise defined herein shall have the meanings given thereto in the Agre
April 27, 2018	DEFA14A	DOVA / Dova Pharmaceuticals, Inc. DEFA14A DEFA14A 1 a18-112663defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commis
April 27, 2018	DEF 14A	DOVA / Dova Pharmaceuticals, Inc. DEF 14A DEF 14A 1 a2235388zdef14a.htm DEF 14A QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary P
April 20, 2018	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File Num
April 3, 2018	8-K	Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38135 81-3858961 (State or Other Jurisdiction of Incorporation) (Commissi
March 27, 2018	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File Num
March 27, 2018	EX-16.1	Letter from KPMG LLP. Exhibit 16.1 March 27, 2018 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for Dova Pharmaceuticals, Inc. and, under the date of February 16, 2018, we reported on the consolidated financial statements of Dova Pharmaceuticals, Inc. as of and for the year ended December 31, 2017 and as of December 31, 2016 and for the period f
March 15, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File Num
February 23, 2018	424B4	? ? ? ? ? ? ? ? Per share Total ? ? ? ? ? ? ? ? Public offering price $ 32.00 $ 80,000,000 Underwriting discounts and commissions(1) $ 1.92 $ 4,800,000 Proceeds to Dova Pharmaceuticals, Inc., before expenses $ 30.08 $ 75,200,000 ? ? ? ? ? ? ? ? 424B4 1 a2234630z424b4.htm 424B4 Use these links to rapidly review the document TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration Statement No. 333-223103 2,500,000 Shares Common Stock We are offering 2,500,000 shares of our common stock. The public offering price is $32.00 per share. Our common stock is listed on The NASDAQ Global Market under the symbol "DOVA." The last reported sa
February 20, 2018	S-1	DOVA / Dova Pharmaceuticals, Inc. S-1 S-1 1 a2234415zs-1.htm S-1 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on February 20, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Dova Pharmaceuticals, Inc. (Exact name of registrant as s
February 20, 2018	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 DOVA PHARMACEUTICALS, INC. [?] Shares of Common Stock, par value $0.001 per share Underwriting Agreement [?], 2018 J. P. Morgan Securities LLC Jefferies LLC Evercore Group L.L.C. c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o Evercore Group L.L.C 55 East 52nd Street New York, New York 10055 Ladies
February 20, 2018	CORRESP	DOVA / Dova Pharmaceuticals, Inc. CORRESP J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Jefferies LLC 520 Madison Avenue New York, NY 10022 Evercore Group L.L.C 55 East 52nd Street New York, New York 10055 February 20, 2018 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7010 Attn: Ms. Ada D. Sarmento Re: Dova Pharmaceuticals, Inc. Registration Statement
February 20, 2018	CORRESP	DOVA / Dova Pharmaceuticals, Inc. CORRESP 240 Leigh Farm Road, Suite 245 VIA EDGAR Durham, NC 27707 February 20, 2018 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Ada D. Sarmento Re: Dova Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-223103 Acceleration Request Requested Date: Thursday, February 22, 2018 Requested Time: 4:30 P.M. Eastern
February 16, 2018	10-K	DOVA / Dova Pharmaceuticals, Inc. 10-K (Annual Report) 10-K 1 a17-28738110k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2017 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commissio
February 16, 2018	EX-21.1	Subsidiaries of the Company Exhibit 21.1 SUBSIDIARIES OF DOVA PHARMACEUTICALS, INC Name of Subsidiary Jurisdiction of Incorporation AkaRx, Inc Delaware Dova Pharmaceuticals Ireland Limited Ireland 1
February 15, 2018	EX-99.1	Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Operating and Financial Results Conference call scheduled for 4:30 p.m. EST today Exhibit 99.1 Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Operating and Financial Results Conference call scheduled for 4:30 p.m. EST today DURHAM, NC, February 15, 2018 ? Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, today reported its o
February 15, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a18-618118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0
February 14, 2018	SC 13G/A	DOVA / Dova Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment Amendment No. 1 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Dova Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 25985T 10 2 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check
February 13, 2018	SC 13G	DOVA / Dova Pharmaceuticals, Inc. / Manning Paul B - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Dova Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 25985T 10 2 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs
January 31, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2018 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File N
January 31, 2018	EX-10.1	Employment Agreement, by and between the Company and Mark W. Hahn, dated as of January 31, 2018 (previously filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-38135), filed with the Commission on January 31, 2018 and incorporated by reference herein) Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective January 31, 2018 (the ?Effective Date?), by and between Dova Pharmaceuticals, Inc., a Delaware corporation (the ?Company?) and Mark W. Hahn (the ?Employee?). The Company desires to employ the Employee in the capacity of full-time Chief Financial Officer pursuant to the terms of this Agreement an
January 26, 2018	DRS	DOVA / Dova Pharmaceuticals, Inc. Use these links to rapidly review the document Table of contents Index to Financial Statements Table of Contents Confidential Treatment Requested by Dova Pharmaceuticals, Inc.
November 28, 2017	EX-99.1	Dova Pharmaceuticals Announces FDA Acceptance of the Avatrombopag New Drug Application (NDA) with Priority Review PDUFA date of May 21, 2018 Exhibit 99.1 Dova Pharmaceuticals Announces FDA Acceptance of the Avatrombopag New Drug Application (NDA) with Priority Review PDUFA date of May 21, 2018 DURHAM, NC, November 27, 2017 ? Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced the New Drug Application (NDA) for avatrombopag has been accepted for filing and has been granted Priority Review by the United States Food and Drug Adminis
November 28, 2017	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2017 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38135 81-3858961 (State or Other Jurisdiction (Commission (IRS Employe
November 9, 2017	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2017 Dova Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2017 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File N
November 9, 2017	EX-99.1	Dova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial Results NDA for avatrombopag submitted to FDA Conference call scheduled for 4:30 p.m. EST today Exhibit 99.1 Dova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial Results NDA for avatrombopag submitted to FDA Conference call scheduled for 4:30 p.m. EST today DURHAM, NC, November 9, 2017 ? Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today reported its operating and financial results for the quarter ended September 30, 2017. Third Quarter and Recent Highlights ? Submission of a
November 9, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38135 DOVA PHARMACEUTICALS,
November 9, 2017	EX-10.1	Amendment to Sublease, by and between the Company and Paidian Research, Inc., dated as of September 22, 2017 (previously filed as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q (File No. 001-38135), filed with the Commission on November 9, 2017, and incorporated by reference herein) EX-10.1 2 a17-206751ex10d1.htm EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO SUBLEASE AGREEMENT THIS FIRST AMENDMENT TO SUBLEASE AGREEMENT (the “Amendment”) is made effective this 22nd day of September 2017 by and between Paidion Research, Inc. a North Carolina corporation (“Sublessor”) and Dova Pharmaceuticals, Inc., a Delaware corporation (“Sublessee”); WHEREAS, Sublessor and Sublessee entered into th
October 23, 2017	EX-99.1	Management Presentation January 2017 Liver Meeting of the American Association for the Study of Liver Diseases October 23rd, 2017 Exhibit 99.1 Management Presentation January 2017 Liver Meeting of the American Association for the Study of Liver Diseases October 23rd, 2017 Disclaimer This presentation contains forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Dova?s current beliefs, expectations and assumptions regarding the fut
October 23, 2017	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2017 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38135 81-3858961 (State or Other Jurisdiction of Incorporation) (Commis
September 22, 2017	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2017 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File
September 22, 2017	EX-99.1	DOVA PHARMACEUTICALS ANNOUNCES NEW DRUG APPLICATION SUBMISSION TO FDA FOR AVATROMBOPAG, A SECOND GENERATION THROMBOPOIETIN RECEPTOR AGONIST Exhibit 99.1 DOVA PHARMACEUTICALS ANNOUNCES NEW DRUG APPLICATION SUBMISSION TO FDA FOR AVATROMBOPAG, A SECOND GENERATION THROMBOPOIETIN RECEPTOR AGONIST DURHAM, NC, September 22, 2017 ? Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a specialty pharmaceutical company, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for avatrombopag, a secon
August 14, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38135 DOVA PHARMACEUTICALS, INC.
August 10, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2017 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File Nu
August 10, 2017	EX-99.1	Dova Pharmaceuticals Reports Second Quarter 2017 Operating and Financial Results NDA submission for avatrombopag expected in the third quarter of 2017 Conference call scheduled for 4:30 p.m. EDT today Exhibit 99.1 Dova Pharmaceuticals Reports Second Quarter 2017 Operating and Financial Results NDA submission for avatrombopag expected in the third quarter of 2017 Conference call scheduled for 4:30 p.m. EDT today DURHAM, NC, August 10, 2017 ? Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today reported its operating and financial results for the quarter ended June 30, 2017. Second Quarter and Recent
August 1, 2017	EX-1	AGREEMENT EX-1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them.
August 1, 2017	SC 13G	DOVA / Dova Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - SCHEDULE 13G Passive Investment SC 13G 1 d414662dsc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Dova Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 25985T 10 2 (CUSIP Number) July 5, 2017 (Date of Event Which Requires Filing of this Statement) Che
July 18, 2017	S-8	As filed with the Securities and Exchange Commission on July 18, 2017 As filed with the Securities and Exchange Commission on July 18, 2017 Registration No.
July 18, 2017	EX-4.6	Form of Stock Option Grant Notice and Stock Option Agreement under Amended and Restated 2017 Equity Incentive Plan. DOVA PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN) Dova Pharmaceuticals, Inc. (the ?Company?), pursuant to its Amended and Restated 2017 Equity Incentive Plan (the ?Plan?), hereby grants to Optionholder an option to purchase the number of shares of the Company?s Common Stock set forth below. This option is subject to all of the terms and conditio
July 5, 2017	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2017 Dova Pharmaceuticals UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2017 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38135 (Commission File Numbe
June 30, 2017	424B4	Per share Total Initial public offering price $ 17.00 $ 75,055,000 Underwriting discounts and commissions(1) $ 1.19 $ 5,253,850 Proceeds to Dova Pharmaceuticals, Inc., before expenses $ 15.81 $ 69,801,150 Use these links to rapidly review the document Table of contents TABLE OF CONTENTS 2 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No.
June 28, 2017	S-1MEF	As filed with the Securities and Exchange Commission on June 28, 2017 As filed with the Securities and Exchange Commission on June 28, 2017 Registration No.
June 26, 2017	8-A12B	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934 Dova Pharmaceuticals, Inc. (Exact Name of Registrant as Specifi SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934 Dova Pharmaceuticals, Inc.
June 26, 2017	CORRESP	J.P. Morgan Securities LLC J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Jefferies LLC 520 Madison Avenue New York, NY 10022 Leerink Partners LLC 299 Park Avenue, 21st Floor New York, NY 10171 June 26, 2017 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7010 Attn: Ms. Suzanne Hayes Ms. Christine Westbrook Ms. Bonnie Baynes Ms. Angela Conn
June 26, 2017	CORRESP	240 Leigh Farm Road, Suite 245 240 Leigh Farm Road, Suite 245 Durham, NC 27707 VIA EDGAR June 26, 2017 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Ms. Suzanne Hayes Ms. Christine Westbrook Ms. Bonnie Baynes Ms. Angela Connell Re: Dova Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-218479 Acceleration Request Request
June 19, 2017	EX-10.11	Amended and Restated 2017 Equity Incentive Plan. Exhibit 10.11 DOVA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 14, 2017 APPROVED BY THE STOCKHOLDERS: June 15, 2017 IPO DATE: , 2017 1. GENERAL. Amendment and Restatement of Prior Plan. The Plan is intended as the amendment and restatement of the Dova Pharmaceuticals, Inc. 2017 Equity Incentive Plan (the ?Prior Plan?). From and afte
June 19, 2017	S-1/A	As filed with the Securities and Exchange Commission on June 19, 2017 Use these links to rapidly review the document Table of contents TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on June 19, 2017 Registration No.
June 19, 2017	EX-3.1.1	CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DOVA PHARMACEUTICALS, INC. Exhibit 3.1.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DOVA PHARMACEUTICALS, INC. DOVA PHARMACEUTICALS, INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST: The name of the corporation is Dova Pharmaceuticals, Inc. (the “Corporation”) and that this cor
June 19, 2017	EX-10.12	Form of Indemnification Agreement with non-employee directors (previously filed as Exhibit 10.12 to Amendment No. 2 to the Company’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 19, 2017, and incorporated by reference herein) Exhibit 10.12 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the ?Agreement?) is made and entered into as of , 2017 between Dova Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and [INDEMNITEE NAME] (?Indemnitee?). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as officers, directors or in other capacities unless they a
June 19, 2017	EX-1.1	DOVA PHARMACEUTICALS, INC. [·] Shares of Common Stock, par value $0.001 per share Underwriting Agreement Exhibit 1.1 DOVA PHARMACEUTICALS, INC. [?] Shares of Common Stock, par value $0.001 per share Underwriting Agreement [?], 2017 J. P. Morgan Securities LLC Jefferies LLC Leerink Partners LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o
June 19, 2017	EX-10.18	Sublease, by and between the Company and Paidian Research, Inc., dated as of June 9, 2017 (previously filed as Exhibit 10.18 to Amendment No. 2 to the Company’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 19, 2017, and incorporated by reference herein) Exhibit 10.18 SUBLEASE AGREEMENT THIS SUBLEASE (the ?Sublease?) is made effective this 9th day of June, 2017 by and between Paidion Research, Inc. a North Carolina corporation (?Sublessor?) and Dova Pharmaceuticals, Inc., a Delaware corporation (?Sublessee?); WHEREAS, Pursuant to that certain Office Lease Agreement dated April 10, 2014 by and between Sublessor, as tenant, and Palladian Center, LLC
June 19, 2017	CORRESP	* * * * Darren DeStefano (703) 456-8034 [email protected] VIA EDGAR June 19, 2017 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Ms. Suzanne Hayes Ms. Christine Westbrook Ms. Bonnie Baynes Ms. Angela Connell Re: Dova Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed June 2, 2017 Amendment No. 1 to Regi
June 12, 2017	CORRESP	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETED ASTERISK, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO 17 CFR §200.83 Cooley LLP One Freedom Square Reston Town Center 11951 Freedom Drive Resto Darren K. DeStefano +1 703 456 8034 [email protected] VIA EDGAR FOIA Confidential Treatment Request June 12, 2017 Confidential Treatment Requested by Dova Pharmaceuticals, Inc. in connection with Registration Statement on Form S-1 (File No. 333-218479) U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Ms. Su
June 9, 2017	EX-3.3	Amended and Restated Certificate of Incorporation (previously filed as Exhibit 3.3 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 9, 2017, and incorporated by reference herein.) Exhibit 3.3 DOVA PHARMACEUTICALS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION DOVA PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware (the ?Company?), does hereby certify as follows: FIRST: The name of the Company is Dova Pharmaceuticals, Inc. SECOND: The Company was originally formed as PBM AKX Holdings, LLC, a limited liability company
June 9, 2017	S-1/A	As filed with the Securities and Exchange Commission on June 9, 2017 Use these links to rapidly review the document Table of contents TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on June 9, 2017 Registration No.
June 9, 2017	EX-3.4	Amended and Restated Bylaws (previously filed as Exhibit 3.4 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 9, 2017, and incorporated by reference herein) EX-3.4 3 a2232389zex-34.htm EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF DOVA PHARMACEUTICALS, INC. (A DELAWARE CORPORATION) [ ], 2017 DOVA PHARMACEUTICALS, INC. AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be established and maintained at the office of Corporation Service Company, in the City of Wilmington, in the County of New Castl
June 9, 2017	EX-10.17	Supply Agreement by and between Eisai, Inc. and AkaRx, Inc., dated June 9, 2017 (previously filed as Exhibit 10.17 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 9, 2017, and incorporated by reference herein) Exhibit 10.17 *Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. ?? 200.80(b)(4) and 230.406 SUPPLY AGREEMENT between Eisai Inc. and AkaRx, Inc. Dated as of June 9, 2017 [*] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230
June 2, 2017	S-1	As filed with the Securities and Exchange Commission on June 2, 2017 Use these links to rapidly review the document Table of contents TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on June 2, 2017 Registration No.
June 2, 2017	EX-10.1	Secured Promissory Note issued by AkaRx, Inc. to Eisai, Inc., dated March 30, 2016 (previously filed as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 2, 2017, and incorporated by reference herein) Exhibit 10.1 ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. ?? 200.80(b)(4) and 230.406 SECURED PROMISSORY NOTE March 30, 2016 FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, AkaRx, Inc., a Delaware corporation (the ?Borrower?), hereby unconditionally promises to pay to the order of Eisai Inc. or its assigns (the ?Lender?), on or
June 2, 2017	EX-10.8	Investors’ Rights Agreement by and among the Company and certain of its stockholders, dated September 19, 2016 (previously filed as Exhibit 10.8 to the Company’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 2, 2017, and incorporated by reference herein) Exhibit 10.8 INVESTORS? RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 4 2.1 Demand Registration 4 2.2 Company Registration 5 2.3 Underwriting Requirements 6 2.4 Obligations of the Company 7 2.5 Furnish Information 8 2.6 Expenses of Registration 8 2.7 Delay of Registration 9 2.8 Indemnification 9 2.9 Reports Under Exchange Act 11 2.10 Limitations on Subsequent Regi
June 2, 2017	EX-2.1	Stock Purchase Agreement by and between Eisai, Inc. and the Company, dated March 29, 2016 (previously filed as Exhibit 2.1 to the Company’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 2, 2017, and incorporated by reference herein) Exhibit 2.1 *Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 STOCK PURCHASE AGREEMENT BETWEEN EISAI INC. and PBM AKX HOLDINGS, LLC Dated as of March 29, 2016 [*] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 20
June 2, 2017	EX-10.6	Services Agreement between the Company and PBM Capital Group, LLC, dated April 1, 2016 (previously filed as Exhibit 10.6 to the Company’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 2, 2017, and incorporated by reference herein) Exhibit 10.6 SERVICES AGREEMENT THIS SERVICES AGREEMENT (this ?Agreement?) is entered into as of the 1st day of April, 2016, by and between PBM Capital Group, LLC, a Delaware limited liability company (?PBM?), and Dova Pharmaceuticals, LLC (the ?Company?). R E C I T A L S A. The Company is engaged in the business of owning and managing, through its wholly owned subsidiary, AkaRx, Inc., a business
June 2, 2017	EX-10.4	License Agreement between Astellas Pharma Inc. and AkaRx, Inc., dated August 15, 2005, as amended (previously filed as Exhibit 10.4 to the Company’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 2, 2017, and incorporated by reference herein) Exhibit 10.4 ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 YM477 LICENSE AGREEMENT This Agreement is made as of August 15, 2005, by and between Astellas Pharma Inc., a company organized and existing under the laws of Japan and having its principal office at 3·11, Nihonbasbi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (“Licensor
June 2, 2017	EX-10.16	Employment Agreement, by and between the Company and Kevin Laliberte, dated as of March 23, 2017 (previously filed as Exhibit 10.16 to the Company’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 2, 2017, and incorporated by reference herein) Exhibit 10.16 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective March 23, 2017 (the ?Effective Date?), by and between Dova Pharmaceuticals, Inc., a Delaware corporation (the ?Company?) and Kevin Laliberte (the ?Employee?). The Company desires to employ the Employee in the capacity of full-time Senior Vice President, Product Development pursuant to the terms
June 2, 2017	EX-21.1	Dova Pharmaceuticals, Inc. List of Subsidiaries Exhibit 21.1 Dova Pharmaceuticals, Inc. List of Subsidiaries Subsidiary Jurisdiction AkaRx, Inc. Delaware
June 2, 2017	EX-10.7	Services Agreement between AkaRx, Inc. and PBM Capital Group, LLC, dated April 1, 2016 (previously filed as Exhibit 10.7 to the Company’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 2, 2017, and incorporated by reference herein) Exhibit 10.7 SERVICES AGREEMENT THIS SERVICES AGREEMENT (this ?Agreement?) is entered into as of the 1st day of April, 2016, by and between PBM Capital Group, LLC, a Delaware limited liability company (?PBM?), and AkaRx, Inc. (the ?Company?). R E C I T A L S A. The Company is engaged in the business of owning, managing and developing a new drug product candidate, commonly referenced as avatrombopa
June 2, 2017	EX-10.15	Employment Agreement, by and between the Company and Lee F. Allen, dated as of April 14, 2017 (previously filed as Exhibit 10.15 to the Company’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 2, 2017, and incorporated by reference herein) Exhibit 10.15 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective April 14, 2017 (the ?Effective Date?), by and between Dova Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Lee F. Allen, M.D., PH.D. (the ?Employee?). The Company desires to employ the Employee in the capacity of full-time Chief Medical Officer pursuant to the terms of this A
June 2, 2017	EX-10.10	Form of Stock Option Grant Notice and Stock Option Agreement under 2017 Equity Incentive Plan (previously filed as Exhibit 10.10 to the Company’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 2, 2017, and incorporated by reference herein) Exhibit 10.10 DOVA PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2017 EQUITY INCENTIVE PLAN) Dova Pharmaceuticals, Inc. (the ?Company?), pursuant to its 2017 Equity Incentive Plan (the ?Plan?), hereby grants to Optionholder an option to purchase the number of shares of the Company?s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this gran
June 2, 2017	EX-10.9	2017 Equity Incentive Plan (previously filed as Exhibit 10.9 to the Company's Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 2, 2017, and incorporated by reference herein) Exhibit 10.9 DOVA PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 28, 2017 APPROVED BY THE STOCKHOLDERS: APRIL 11, 2017 TERMINATION DATE: MARCH 27, 2027 1. GENERAL. (a) Eligible Stock Award Recipients. Employees, Directors and Consultants are eligible to receive Stock Awards. (b) Available Stock Awards. The Plan provides for the grant of the following type
June 2, 2017	CORRESP	Divakar Gupta (212) 479-6474 [email protected] VIA EDGAR Divakar Gupta (212) 479-6474 [email protected] VIA EDGAR June 2, 2017 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Ms. Suzanne Hayes Ms. Christine Westbrook Ms. Bonnie Baynes Ms. Angela Connell Re: Dova Pharmaceuticals, Inc. Confidential Draft Registration Statement on Form S-1 Submitted April 21, 2017 CIK No
June 2, 2017	EX-10.14	Employment Agreement, by and between the Company and Douglas Blankenship, dated as of March 1, 2017 (previously filed as Exhibit 10.14 to the Company's Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 2, 2017, and incorporated by reference herein) Exhibit 10.14 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective March 1, 2017 (the ?Effective Date?), by and between Dova Pharmaceuticals, Inc., a Delaware corporation (the ?Company?) and Doug Blankenship (the ?Employee?). The Company desires to employ the Employee in the capacity of full-time Chief Financial Officer pursuant to the terms of this Agreement
June 2, 2017	EX-10.3	Guarantee by PBM Capital Investments, LLC in favor of Eisai, Inc., dated March 30, 2016 (previously filed as Exhibit 10.3 to the Company’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 2, 2017, and incorporated by reference herein) Exhibit 10.3 EXECUTION VERSION GUARANTEE This Guarantee is made by PBM Capital Investments, LLC, a Delaware limited liability company (?Guarantor?), in favor of Eisai Inc., a Delaware corporation (?Seller?), as of March 30, 2016 (this ?Guarantee?). Guarantor and Seller are sometimes referred to herein individually as a ?Party? and collectively as the ?Parties?. Any capitalized or other terms defin
June 2, 2017	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DOVA PHARMACEUTICALS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DOVA PHARMACEUTICALS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Dova Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. T
June 2, 2017	EX-10.2	Security Agreement by and between AkaRx, Inc. and Eisai, Inc., dated March 30, 2016 (previously filed as Exhibit 10.2 to the Company’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 2, 2017, and incorporated by reference herein) Exhibit 10.2 Execution Version SECURITY AGREEMENT This Security Agreement (“Security Agreement”) is made as of March 30, 2016, by and between AkaRx, Inc., a Delaware corporation (“Debtor”), and Eisai Inc., a Delaware corporation (“Secured Party”). Debtor and Secured Party are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” WHEREAS, Debtor and Secured Party
June 2, 2017	EX-3.2	BYLAWS DOVA PHARMACEUTICALS, INC. ARTICLE I Exhibit 3.2 BYLAWS OF DOVA PHARMACEUTICALS, INC. ARTICLE I OFFICES Section 1. Principal Office. The principal office of Dova Pharmaceuticals, Inc. (the ?Company?) shall be located in Charlottesville, Virginia, or at such other place within or without the State of Delaware as the Board of Directors may from time to time determine. Section 2. Additional Offices. The Company may have such additional
June 2, 2017	EX-10.5	Transition Services Agreement by and between Eisai, Inc. and AkaRx, Inc., dated March 30, 2016 (previously filed as Exhibit 10.5 to the Company's Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 2, 2017, and incorporated by reference herein) Exhibit 10.5 *Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. ?? 200.80(b)(4) and 230.406 TRANSITION SERVICES AGREEMENT by and between Eisai Inc. and AkaRx, Inc. Dated as of March 30, 2016 [*] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections
June 2, 2017	EX-10.13	Employment Agreement, by and between the Company and Alexander C. Sapir, dated as of January 3, 2017 (previously filed as Exhibit 10.13 to the Company’s Registration Statement on Form S-1 (File No. 333-218479), filed with the Commission on June 2, 2017, and incorporated by reference herein) Exhibit 10.13 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective January 3, 2017 (the ?Effective Date?), by and between Dova Pharmaceuticals, Inc., a Delaware corporation (the ?Company?) and Alexander C. Sapir (the ?Employee?). The Company desires to employ the Employee in the capacity of full-time President and CEO pursuant to the terms of this Agreement an
April 21, 2017	EX-10.1	SECURED PROMISSORY NOTE EX-10.1 4 filename4.htm Exhibit 10.1 ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 SECURED PROMISSORY NOTE March 30, 2016 FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, AkaRx, Inc., a Delaware corporation (the “Borrower”), hereby unconditionally promises to pay to the order of Eisai Inc. or its assig
April 21, 2017	EX-21.1	Dova Pharmaceuticals, Inc. List of Subsidiaries Exhibit 21.1 Dova Pharmaceuticals, Inc. List of Subsidiaries Subsidiary Jurisdiction AkaRx, Inc. Delaware
April 21, 2017	EX-10.9	DOVA PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 28, 2017 APPROVED BY THE STOCKHOLDERS: APRIL 11, 2017 TERMINATION DATE: MARCH 27, 2027 Exhibit 10.9 DOVA PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 28, 2017 APPROVED BY THE STOCKHOLDERS: APRIL 11, 2017 TERMINATION DATE: MARCH 27, 2027 1. GENERAL. (a) Eligible Stock Award Recipients. Employees, Directors and Consultants are eligible to receive Stock Awards. (b) Available Stock Awards. The Plan provides for the grant of the following type
April 21, 2017	EX-10.14	EMPLOYMENT AGREEMENT Exhibit 10.14 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective March 1, 2017 (the ?Effective Date?), by and between Dova Pharmaceuticals, Inc., a Delaware corporation (the ?Company?) and Doug Blankenship (the ?Employee?). The Company desires to employ the Employee in the capacity of full-time Chief Financial Officer pursuant to the terms of this Agreement
April 21, 2017	EX-10.15	EMPLOYMENT AGREEMENT EX-10.15 15 filename15.htm Exhibit 10.15 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective April 14, 2017 (the “Effective Date”), by and between Dova Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Lee F. Allen, M.D., PH.D. (the “Employee”). The Company desires to employ the Employee in the capacity of full-time Chief Medical Officer purs
April 21, 2017	EX-2.1	STOCK PURCHASE AGREEMENT EISAI INC. PBM AKX HOLDINGS, LLC Dated as of March 29, 2016 EX-2.1 2 filename2.htm Exhibit 2.1 *Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 STOCK PURCHASE AGREEMENT BETWEEN EISAI INC. and PBM AKX HOLDINGS, LLC Dated as of March 29, 2016 [*] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested unde
April 21, 2017	EX-10.5	TRANSITION SERVICES AGREEMENT by and between Eisai Inc. AkaRx, Inc. Dated as of March 30, 2016 EX-10.5 8 filename8.htm Exhibit 10.5 *Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 TRANSITION SERVICES AGREEMENT by and between Eisai Inc. and AkaRx, Inc. Dated as of March 30, 2016 [*] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested
April 21, 2017	EX-10.10	DOVA PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2017 EQUITY INCENTIVE PLAN) Exhibit 10.10 DOVA PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2017 EQUITY INCENTIVE PLAN) Dova Pharmaceuticals, Inc. (the ?Company?), pursuant to its 2017 Equity Incentive Plan (the ?Plan?), hereby grants to Optionholder an option to purchase the number of shares of the Company?s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this gran
April 21, 2017	EX-10.6	SERVICES AGREEMENT Exhibit 10.6 SERVICES AGREEMENT THIS SERVICES AGREEMENT (this ?Agreement?) is entered into as of the 1st day of April, 2016, by and between PBM Capital Group, LLC, a Delaware limited liability company (?PBM?), and Dova Pharmaceuticals, LLC (the ?Company?). R E C I T A L S A. The Company is engaged in the business of owning and managing, through its wholly owned subsidiary, AkaRx, Inc., a business
April 21, 2017	EX-3.2	BYLAWS DOVA PHARMACEUTICALS, INC. ARTICLE I Exhibit 3.2 BYLAWS OF DOVA PHARMACEUTICALS, INC. ARTICLE I OFFICES Section 1. Principal Office. The principal office of Dova Pharmaceuticals, Inc. (the ?Company?) shall be located in Charlottesville, Virginia, or at such other place within or without the State of Delaware as the Board of Directors may from time to time determine. Section 2. Additional Offices. The Company may have such additional
April 21, 2017	DRS	As submitted to the Securities and Exchange Commission confidentially on April 21, 2017 Use these links to rapidly review the document Table of contents TABLE OF CONTENTS 2 Table of Contents As submitted to the Securities and Exchange Commission confidentially on April 21, 2017 Registration No.
April 21, 2017	EX-10.13	EMPLOYMENT AGREEMENT Exhibit 10.13 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective January 3, 2017 (the ?Effective Date?), by and between Dova Pharmaceuticals, Inc., a Delaware corporation (the ?Company?) and Alexander C. Sapir (the ?Employee?). The Company desires to employ the Employee in the capacity of full-time President and CEO pursuant to the terms of this Agreement an
April 21, 2017	EX-10.7	SERVICES AGREEMENT Exhibit 10.7 SERVICES AGREEMENT THIS SERVICES AGREEMENT (this “Agreement”) is entered into as of the 1st day of April, 2016, by and between PBM Capital Group, LLC, a Delaware limited liability company (“PBM”), and AkaRx, Inc. (the “Company”). R E C I T A L S A. The Company is engaged in the business of owning, managing and developing a new drug product candidate, commonly referenced as avatrombopa
April 21, 2017	EX-10.2	SECURITY AGREEMENT Exhibit 10.2 Execution Version SECURITY AGREEMENT This Security Agreement (?Security Agreement?) is made as of March 30, 2016, by and between AkaRx, Inc., a Delaware corporation (?Debtor?), and Eisai Inc., a Delaware corporation (?Secured Party?). Debtor and Secured Party are sometimes referred to herein individually as a ?Party? and collectively as the ?Parties.? WHEREAS, Debtor and Secured Party
April 21, 2017	EX-10.3	[The remainder of this page is left blank intentionally.] Exhibit 10.3 EXECUTION VERSION GUARANTEE This Guarantee is made by PBM Capital Investments, LLC, a Delaware limited liability company (?Guarantor?), in favor of Eisai Inc., a Delaware corporation (?Seller?), as of March 30, 2016 (this ?Guarantee?). Guarantor and Seller are sometimes referred to herein individually as a ?Party? and collectively as the ?Parties?. Any capitalized or other terms defin
April 21, 2017	EX-10.4	YM477 LICENSE AGREEMENT Exhibit 10.4 ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 YM477 LICENSE AGREEMENT This Agreement is made as of August 15, 2005, by and between Astellas Pharma Inc., a company organized and existing under the laws of Japan and having its principal office at 3·11, Nihonbasbi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (“Licensor

DOVA / Dova Pharmaceuticals, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)